CD274 and neoplasm: With the goal to suppress the brake for the anti-tumor immune response created by the PDL1/PD-1 interaction, immune checkpoint inhibitors (ICIs) administered jointly with RT could have a synergistic effect, tipping the balance in favor of a proimmunogenic tumor microenvironment [122].